Perspectives

3:36
Daratumumab practical considerations in MM
Torben Plesner
0:47
Patient monitoring following CAR T-cell therapy
Erik Aerts
1:24
Educational material for HCPs on CAR T-cell therapy
Erik Aertes
1:06
The role of nurses in apheresis during CAR T-cell therapy
Erik Aerts
1:29
Settings for CAR T-cell therapy
Erik Aerts
0:48
HCP collaboration in CAR-T cell therapy
Erik Aerts
1:09
The promise of CAR T-cell therapy in hematological malignancies
Emanuele Ostuni
3:08
CAR T-cell therapy: the patient’s perspective
Bregje Verhoeven
1:28
Potential of CAR T-cells entering the mainstream of cancer treatment
Valentín Ortiz-Maldonado
2:18
Advice for HCPs wanting to get into hematology clinical trials
Simon Rule
3:22
How increasing bureaucracy is affecting clinical research: self-defeating?
Simon Rule
2:56
The future landscape of CAR T-cell therapy
Elaine Vickers
4:48
The quality control measures recommended within the JACIE model
Eoin McGrath
3:49
The limitations of immunotherapy with CAR T-cells
Elaine Vickers
3:07
CAR T-cell therapy: cancer immunotherapy beyond checkpoint inhibitors
Elaine Vickers
1:29
Settings for CAR T-cell therapy
Erik Aerts
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals